ReviewThe archives of bone and joint surgery2018
Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review.
Review in The archives of bone and joint surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review.Clinical orthopaedics and related research · 2020Pooled it
- A Rare Pediatric Giant Cell Tumor of the Clivus Bone, H3.3 p.Gly35Trp-mutated: Case Report and Mini-review of the Literature.Turkish archives of pediatrics · 2025Article
- Excellent Results in the Off-Label Use of Denosumab in Pediatric Oncology: Monocentric Case Series Study.Case reports in pediatrics · 2025Article
- A Short Course of Preoperative Denosumab Injection Followed by Surgery in High-Risk Giant Cell Tumors of the Extremities: A Retrospective Study.Indian journal of surgical oncology · 2024Article
- Giant cell tumor of the cervical spine: A very uncommon cause for cervical spine compression.Radiology case reports · 2024Article
- Article
- Functional Outcomes of Limb Salvage Surgery in Patients with Giant Cell Tumor of Bone of the Lower Extremities: A Cross-sectional Comparative Study.Acta medica Philippina · 2024Article
- Clinical Outcome of Extended Curettage with Postoperative Denosumab Administration for the Treatment of Campanacci Grade III Giant Cell Tumors of the Extremities.Cancer management and research · 2024Article
- Denosumab for giant cell tumors of bone from 2010 to 2022: a bibliometric analysis.Clinical and experimental medicine · 2023Review
- The Role of Denosumab in the Treatment of Primary Tumors of Bone.The Journal of hand surgery · 2023Review
- Review
- Current therapies and future prospective for locally aggressive mesenchymal tumors.Frontiers in oncology · 2023Review
- Establishment and characterization of NCC-GCTB5-C1: a novel cell line of giant cell tumor of bone.Human cell · 2022Article
- The Activation of PDGFRβ on Mononuclear Stromal/Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment. An Immunohistochemical Study of Five Cases.Pathology oncology research : POR · 2022Article
- Should Denosumab or Radical Surgery Be Recommended for a Spinal Giant Cell Tumour in a Fertile Female?Cureus · 2020Article
- Radiological Features of Giant Cell Tumours of Bone.Cureus · 2020Article
- [Osteoid-forming bone tumors : Morphology and current translational cell biology].Der Pathologe · 2020Review
- The functional outcomes and complications of different reconstruction methods for Giant cell tumor of the distal radius: comparison of Osteoarticular allograft and three-dimensional-printed prosthesis.BMC musculoskeletal disorders · 2020Article
- One-Step Reconstruction with a Novel Suspended, Modular, and 3D-Printed Total Sacral Implant Resection of Sacral Giant Cell Tumor with Preservation of Bilateral SOrthopaedic surgery · 2020Article
- Three-dimensional printed, proximal phalangeal prosthesis with metatarsophalangeal joint arthroplasty for the treatment of a giant cell tumor of the fifth toe: The first case report.International journal of surgery case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies suggest that Denosumab reduces tumor size, therefore, makes the surgery easier with lower morbidity. However, some studies have reported several complications for this drug. So, this systematic review was performed to determine the effectiveness and safety of Denosumab in reducing bone destructions activity of giant cell tumor and skeletal-related events (SRE) in affected patients with giant cell tumor of bone (GCTB) and its recurrence. We explored studies in PubMed, and Cochrane Library. For this purpose, articles of various levels were retrieved until October 22, 2016. Two reviewers assessed the articles independently based on predefined criteria to extract the relevant data. Primary outcomes associated with skeletal-related event, overall survival, and secondary outcomes such as pain, quality of life and adverse events were evaluated and analyzed. The total population of this meta-analysis consisted of 686 patients. Of this population, 55% had primary GCTB and 45% had giant cell tumor recurrence, with 2% experiencing secondary recurrence. The results showed the effectiveness of Denosumab in reducing the tumor size due to inhibiting the Osteoclastogenesis. Denosumab didnot show any effect on reducing tumor recurrence, but, in cases where complete tumor surgery is not possible and tumor residuals may remain, Denosumab can be helpful. Also, the clinicians should consider the risk benefit of Denosumab.
Indexed as
Identifiers
30175172PMC6110426W2792183050What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.